# Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer

> **NCT00232206** · PHASE2 · TERMINATED · sponsor: **Providence Health & Services** · enrollment: 40 (estimated)

## Conditions studied

- Non-small-Cell Lung Carcinoma

## Interventions

- **DRUG:** Neoadjuvant Therapy with Cisplatin Plus Docetaxel

## Key facts

- **NCT ID:** NCT00232206
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-05
- **Primary completion:** 2007-04
- **Final completion:** 2007-11
- **Target enrollment:** 40 (ESTIMATED)
- **Why stopped:** study terminated due to slow accrual
- **Last updated:** 2011-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00232206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00232206, "Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00232206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*